Can Lunit’s AI pathology partnership accelerate cancer biomarker discovery?
Lunit will integrate its SCOPE artificial intelligence pathology platform into Discovery Life Sciences' tissue analysis services, expanding access to standardized biomarker research. The collaboration strengthens Lunit's precision oncology strategy, although financial terms, client adoption and new clinical validation outcomes remain undisclosed.
